SMT201600070B - Derivati di 2-(2,4,5-anilino-sostituita) pirimidina come modulatori di egfr utili per trattare il cancro - Google Patents

Derivati di 2-(2,4,5-anilino-sostituita) pirimidina come modulatori di egfr utili per trattare il cancro

Info

Publication number: SMT201600070B
Authority: SM; San Marino
Prior art keywords: anylin; pyrimidine; derivatives; substituted; treating cancer
Prior art date: 2011-07-27

Application number

SM201600070T

Other languages

English (en)

Italian (it)

Inventor

Sam Butterworth

Maurice Raymond Verschoyle Finlay

Richard Andrew Ward

Vasantha Krishna Kadambar

Chandrasekhara Reddy Chintakuntla

Andiappan Murugan

Heather Marie Redfearn

Claudio Edmundo Chuaqui

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-27

Filing date

2016-03-10

Publication date

2016-04-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46875901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600070(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-03-10 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2016-04-29 Publication of SMT201600070B publication Critical patent/SMT201600070B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Luminescent Compositions (AREA)
Inks, Pencil-Leads, Or Crayons (AREA)
Compositions Of Macromolecular Compounds (AREA)
Liquid Crystal Substances (AREA)

SM201600070T 2011-07-27 2016-03-10 Derivati di 2-(2,4,5-anilino-sostituita) pirimidina come modulatori di egfr utili per trattare il cancro SMT201600070B (it)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161512061P	2011-07-27	2011-07-27
US201261591363P	2012-01-27	2012-01-27
PCT/GB2012/051783 WO2013014448A1 (en)	2011-07-27	2012-07-25	2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer

Publications (1)

Publication Number	Publication Date
SMT201600070B true SMT201600070B (it)	2016-04-29

Family

ID=46875901

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SM20200208T SMT202000208T1 (it)	2011-07-27	2012-07-25	Derivati di 2-(2,4,5-anilino-sostituita) pirimidina come modulatori di egfr utili per trattare il cancro
SM20210652T SMT202100652T1 (it)	2011-07-27	2012-07-25	Composti di 2-(2,4,5-anilino-sostituita) pirimidina
SM201600070T SMT201600070B (it)	2011-07-27	2016-03-10	Derivati di 2-(2,4,5-anilino-sostituita) pirimidina come modulatori di egfr utili per trattare il cancro

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
SM20200208T SMT202000208T1 (it)	2011-07-27	2012-07-25	Derivati di 2-(2,4,5-anilino-sostituita) pirimidina come modulatori di egfr utili per trattare il cancro
SM20210652T SMT202100652T1 (it)	2011-07-27	2012-07-25	Composti di 2-(2,4,5-anilino-sostituita) pirimidina

Country Status (38)

Country	Link
US (8)	US8946235B2 (xx)
EP (7)	EP4119551A1 (xx)
JP (3)	JP5427321B2 (xx)
KR (3)	KR101691268B1 (xx)
CN (7)	CN104109151B (xx)
AR (1)	AR087336A1 (xx)
AU (1)	AU2012288626C1 (xx)
BR (4)	BR122014026150B1 (xx)
CA (5)	CA2881987C (xx)
CL (1)	CL2013003281A1 (xx)
CO (1)	CO6811863A2 (xx)
CR (1)	CR20130629A (xx)
CY (4)	CY1117431T1 (xx)
DK (5)	DK3009431T3 (xx)
DO (1)	DOP2013000263A (xx)
EA (3)	EA033733B1 (xx)
EC (1)	ECSP13013033A (xx)
ES (5)	ES2564671T3 (xx)
GT (1)	GT201300288A (xx)
HR (4)	HRP20160135T1 (xx)
HU (4)	HUE026429T2 (xx)
IL (6)	IL229199A (xx)
LT (3)	LT3686194T (xx)
ME (3)	ME03785B (xx)
MX (3)	MX2014000528A (xx)
MY (2)	MY161925A (xx)
NI (1)	NI201300134A (xx)
PE (1)	PE20141700A1 (xx)
PH (2)	PH12013502312A1 (xx)
PL (5)	PL3333161T3 (xx)
PT (4)	PT3686193T (xx)
RS (4)	RS62542B1 (xx)
SG (5)	SG10201910984XA (xx)
SI (4)	SI2736895T1 (xx)
SM (3)	SMT202000208T1 (xx)
TW (3)	TWI555743B (xx)
UY (1)	UY34219A (xx)
WO (1)	WO2013014448A1 (xx)

Families Citing this family (223)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA029131B1 (ru)	2008-05-21	2018-02-28	Ариад Фармасьютикалз, Инк.	Фосфорсодержащие производные в качестве ингибиторов киназы
US9273077B2 (en)	2008-05-21	2016-03-01	Ariad Pharmaceuticals, Inc.	Phosphorus derivatives as kinase inhibitors
BRPI0918868B8 (pt)	2008-09-18	2021-05-25	Naurex Inc	compostos moduladores do receptor de nmda e composições compreendendo os mesmos
EP2467387B1 (en)	2009-08-20	2015-01-07	Karus Therapeutics Limited	Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors.
CA2832504C (en)	2011-05-04	2019-10-01	Ariad Pharmaceuticals, Inc.	Compounds for inhibiting cell proliferation in egfr-driven cancers
JP5427321B2 (ja)	2011-07-27	2014-02-26	アストラゼネカアクチボラグ	２−（２，４，５−置換−アニリノ）ピリミジン化合物
GB201204125D0 (en)	2012-03-08	2012-04-25	Karus Therapeutics Ltd	Compounds
AU2013204563B2 (en)	2012-05-05	2016-05-19	Takeda Pharmaceutical Company Limited	Compounds for inhibiting cell proliferation in EGFR-driven cancers
LT3514158T (lt)	2013-01-29	2023-02-10	Aptinyx Inc.	Spirolaktaminiai nmda receptoriaus moduliatoriai ir jų panaudojimas
PE20151427A1 (es) *	2013-01-29	2015-10-10	Naurex Inc	Moduladores de receptores nmda de espiro-lactama y sus usos
WO2014144326A1 (en)	2013-03-15	2014-09-18	G1 Therapeutics, Inc.	Transient protection of normal cells during chemotherapy
US9611283B1 (en)	2013-04-10	2017-04-04	Ariad Pharmaceuticals, Inc.	Methods for inhibiting cell proliferation in ALK-driven cancers
WO2014210354A1 (en) *	2013-06-28	2014-12-31	Genentech, Inc.	Azaindazole compounds as inhibitors of t790m containing egfr mutants
CN104292142B (zh) *	2013-07-17	2019-05-14	天津大地康和医药技术有限公司	一种n-芳基杂环丁烷脱芳基方法
CN111285813A (zh)	2013-08-23	2020-06-16	润新生物公司	化学实体、组合物和方法
AR098136A1 (es)	2013-10-21	2016-05-04	Merck Patent Gmbh	Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
GB201400034D0 (en)	2014-01-02	2014-02-19	Astrazeneca Ab	Pharmaceutical Compositions comprising AZD9291
CN104761544B (zh) *	2014-01-03	2019-03-15	北京轩义医药科技有限公司	Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
GB201402431D0 (en)	2014-02-12	2014-03-26	Karus Therapeutics Ltd	Compounds
CN104860941B (zh) *	2014-02-25	2017-03-22	上海海雁医药科技有限公司	2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
PL3125885T3 (pl) *	2014-04-04	2021-12-06	Astrazeneca Ab	Kombinacja inhibitora EGFR i inhibitora MEK do zastosowania w leczeniu nowotworu złośliwego z mutacją NRAS
CA2946538A1 (en)	2014-04-04	2015-10-08	Del Mar Pharmaceuticals	Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2015175632A1 (en) *	2014-05-13	2015-11-19	Ariad Pharmaceuticals, Inc.	Heteroaryl compounds for kinase inhibition
CN111875585B (zh) *	2014-06-12	2023-06-23	上海艾力斯医药科技股份有限公司	一类激酶抑制剂
KR102628356B1 (ko) *	2014-06-19	2024-01-24	다케다 야쿠힌 고교 가부시키가이샤	키나제 저해를 위한 헤테로아릴 화합물
CN105254615B (zh) *	2014-07-11	2017-02-22	杭州华东医药集团新药研究院有限公司	苯胺嘧啶衍生物及其在制备抗恶性肿瘤药物中的用途
CN105315285B (zh) *	2014-07-25	2017-12-08	上海海雁医药科技有限公司	2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途
CN105315259B (zh) *	2014-07-29	2018-03-09	上海艾力斯医药科技有限公司	吡啶胺基嘧啶衍生物、其制备方法及应用
JO3589B1 (ar)	2014-08-06	2020-07-05	Novartis Ag	مثبطات كيناز البروتين c وطرق استخداماتها
CN104140418B (zh) *	2014-08-15	2016-08-24	常州润诺生物科技有限公司	2-(2，4，5-取代苯胺)嘧啶衍生物及其用途
WO2016029839A1 (zh) *	2014-08-25	2016-03-03	四川海思科制药有限公司	一种（取代的苯基）（取代的嘧啶）胺基衍生物及其制备方法和药物用途
CN104356040A (zh) *	2014-09-17	2015-02-18	爱斯特（成都）生物制药有限公司	一种1-二苯甲基-3-羟基氮杂环丁烷盐酸盐的制备方法
CN105461695B (zh) *	2014-09-29	2018-03-27	齐鲁制药有限公司	嘧啶或三嗪衍生物及其制备方法和用途
CN105524068B (zh) *	2014-09-30	2017-11-24	上海海雁医药科技有限公司	氮杂双环衍生物、其制法与医药上的用途
CN105237515B (zh) *	2014-10-10	2018-06-05	益方生物科技（上海）有限公司	氘代嘧啶类化合物、其制备方法、药物组合物和用途
DK3205650T3 (da) *	2014-10-11	2021-09-13	Shanghai Hansoh Biomedical Co Ltd	Egfr-hæmmer og fremstilling og anvendelse deraf
PT4421069T (pt)	2014-10-13	2026-01-12	Yuhan Corp	Compostos e composições para modular atividades da cinase do egfr mutante
CN105085489B (zh) *	2014-11-05	2019-03-01	益方生物科技（上海）有限公司	嘧啶或吡啶类化合物、其制备方法和医药用途
US10507210B2 (en) *	2014-12-03	2019-12-17	Auckland Uniservices Limited	Kinase inhibitor prodrug for the treatment of cancer
US10590111B2 (en)	2014-12-11	2020-03-17	Beta Pharma, Inc.	Substituted 2-anilinopyrimidine derivatives as EGFR modulators
CN107406442B (zh)	2014-12-23	2021-08-17	达纳－法伯癌症研究所公司	作为egfr抑制剂的新的嘧啶和治疗病症的方法
CN104788427B (zh) *	2015-02-05	2017-05-31	上海泓博智源医药股份有限公司	3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
CN104961731A (zh) *	2015-02-05	2015-10-07	苏州晶云药物科技有限公司	一种表皮生长因子受体抑制剂的磷酸盐、其晶型及制备方法
CN107613769A (zh)	2015-02-17	2018-01-19	润新生物公司	某些化学实体、组合物和方法
CN107973791B (zh)	2015-04-29	2020-04-07	南京圣和药业股份有限公司	稠环或三环芳基嘧啶化合物用作激酶抑制剂
TWI685494B (zh) *	2015-04-29	2020-02-21	大陸商廣東眾生藥業股份有限公司	稠環或三環芳基嘧啶化合物用作激酶抑制劑
CN104817541B (zh) *	2015-05-11	2017-06-16	苏州东南药业股份有限公司	一种抗肿瘤药物的合成方法
HK1251567A1 (zh) *	2015-05-13	2019-02-01	Ariad Pharmaceuticals, Inc.	用於激酶抑制的杂芳基化合物
WO2016185333A1 (en)	2015-05-15	2016-11-24	Novartis Ag	Methods for treating egfr mutant cancers
CN104910049B (zh)	2015-06-16	2016-06-29	苏州明锐医药科技有限公司	Azd9291中间体及其制备方法
RU2734849C2 (ru) *	2015-07-16	2020-10-23	Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд.	Производные анилинпиримидина и их применения
WO2017015363A1 (en) *	2015-07-20	2017-01-26	Dana-Farber Cancer Institute, Inc.	Novel pyrimidines as egfr inhibitors and methods of treating disorders
CN107531678B (zh) *	2015-07-24	2020-12-22	上海海雁医药科技有限公司	Egfr抑制剂及其药学上可接受的盐和多晶型物及其应用
CN105001208A (zh) *	2015-08-06	2015-10-28	南京雷科星生物技术有限公司	一种表皮生长因子受体egfr抑制剂及其制备方法与用途
GB201514760D0 (en)	2015-08-19	2015-09-30	Karus Therapeutics Ltd	Compounds and method of use
GB201514758D0 (en)	2015-08-19	2015-09-30	Karus Therapeutics Ltd	Formulation
GB201514751D0 (en)	2015-08-19	2015-09-30	Karus Therapeutics Ltd	Compounds
GB201514754D0 (en)	2015-08-19	2015-09-30	Karus Therapeutics Ltd	Compounds
CN106117185B (zh) *	2015-08-31	2017-11-07	广州必贝特医药技术有限公司	2,4‑二含氮基团取代嘧啶类化合物及其制备方法和应用
KR102051609B1 (ko) *	2015-08-31	2019-12-03	우시 상량 바이오테크놀로지 씨오., 엘티디.	2-아릴아미노피리딘, 피리미딘 또는 트리아진 유도체 및 그 제조방법과 사용
CN106478605A (zh) *	2015-09-02	2017-03-08	上海页岩科技有限公司	嘧啶类化合物、其制备方法和医药用途
RU2606949C9 (ru) *	2015-11-19	2018-03-14	ЗАО "Р-Фарм"	Замещенные N-{ 3-[4-(1-метил-1Н-индол-3-ил)пиримидин-2-иламино]-4-метоксифенил} -амиды в качестве модуляторов EGFR, предназначенные для лечения рака
RU2603960C1 (ru) *	2015-11-19	2016-12-10	Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм")	Дихлорацетат n1,n2-дизамещенного n4-[4-(1-метил-1н-индол-3-ил)-пиримидин-2-ил]-5-метоксибензол-1,2,4-триамина в качестве модулятора egfr для лечения рака
CN106749267B (zh) *	2015-11-23	2020-08-21	南京圣和药业股份有限公司	新的表皮生长因子受体抑制剂及其应用
CN106810553B (zh) *	2015-11-30	2020-03-17	江苏正大丰海制药有限公司	3-(4,5-取代氨基嘧啶)苯基衍生物及其应用
EP3383877B1 (en) *	2015-12-03	2021-09-15	Zhejiang Jianfeng-Yien Biotechnology Co., Ltd.	Heterocycle compounds and uses thereof
JP6978002B2 (ja) *	2015-12-03	2021-12-08	チョーチアンチアンフェン−イエンバイオテクノロジーカンパニーリミテッド	チエノ−ピリミジン誘導体およびその使用
CN105601620A (zh) *	2015-12-25	2016-05-25	北京康立生医药技术开发有限公司	一种甲磺酸迈瑞替尼的制备方法
CN106928150B (zh)	2015-12-31	2020-07-31	恩瑞生物医药科技（上海）有限公司	丙烯酰胺苯胺衍生物及其药学上的应用
JP2019501222A (ja)	2016-01-07	2019-01-17	シーエスファーマテックリミテッド	Ｅｇｆｒチロシンキナーゼの臨床的に重要な変異体の選択的阻害薬
CN105646454B (zh) *	2016-01-19	2018-05-08	浙江大学	含异羟肟酸片段的2-芳胺基嘧啶类衍生物及制备和应用
CN108530429B (zh) *	2016-01-22	2021-04-27	焦玉奇	2-(2,4,5-取代苯胺)嘧啶衍生物
CN106995437A (zh) *	2016-01-22	2017-08-01	齐鲁制药有限公司	取代吲哚或吲唑嘧啶衍生物及其制备方法和用途
TWI745345B (zh)	2016-02-01	2021-11-11	瑞典商阿斯特捷利康公司	製備奧希替尼（osimertinib，azd9291）或其鹽及「azd9291苯胺」或其鹽的改良方法
CN107043368B (zh) *	2016-02-05	2020-07-31	齐鲁制药有限公司	芳胺嘧啶化合物及其盐的结晶
CN107043369A (zh) *	2016-02-06	2017-08-15	焦玉奇	2‑(2,4,5‑取代苯胺)嘧啶衍生物
CN107098887B (zh) *	2016-02-22	2019-08-09	复旦大学	嘧啶类化合物
CN105585557B (zh) *	2016-02-25	2018-06-22	清华大学	用于靶向治疗癌症的egfr抑制剂及其制备方法与应用
CN105777716B (zh) *	2016-02-25	2018-04-10	清华大学	一种用于靶向治疗癌症的egfr抑制剂及其制备方法与应用
CN105646467B (zh) *	2016-02-25	2018-07-20	黄燕鸽	一种抗癌化合物奥美替尼及其合成方法
CN107163026B (zh) *	2016-03-07	2019-07-02	上海艾力斯医药科技有限公司	吡啶胺基嘧啶衍生物的盐及其制备方法和应用
CN107163027B (zh) *	2016-03-07	2019-11-05	上海艾力斯医药科技有限公司	吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用
CN107188888A (zh) *	2016-03-15	2017-09-22	罗欣生物科技（上海）有限公司	一种制备甲磺酸迈瑞替尼的方法
KR102765652B1 (ko) *	2016-03-22	2025-02-11	장쑤 한서 파마슈티칼 그룹 캄파니 리미티드	Egfr 억제제 유리 염기 또는 산 염 다결정질형, 이의 제조방법 및 응용
BR112018072887A2 (pt)	2016-05-11	2019-03-06	Beta Pharma, Inc.	método de tratamento de câncer de cérebro em um indivíduo, e utilização de um composto
KR102128675B1 (ko)	2016-05-19	2020-06-30	앱티닉스 인크.	스피로-락탐 nmda 수용체 조정제 및 그의 용도
WO2017201285A1 (en)	2016-05-19	2017-11-23	Aptinyx Inc.	Spiro-lactam nmda receptor modulators and uses thereof
MX383920B (es) *	2016-05-26	2025-03-14	Recurium Ip Holdings Llc	Compuestos inhibidores de egfr.
EA201892661A1 (ru)	2016-06-17	2019-07-31	Бета Фарма, Инк.	Фармацевтические соли n-(2-(2-(диметиламино)этокси)-4-метокси-5-((4-(1-метил-1h-индол-3-ил)пиримидин-2-ил)амино)фенил)акриламида и их кристаллические формы
CN107522690B (zh) *	2016-06-20	2022-08-05	海南先声药业有限公司	一种Osimertinib的制备方法
CN107540661A (zh) *	2016-06-24	2018-01-05	正大天晴药业集团股份有限公司	作为egfr抑制剂的苯胺嘧啶化合物的结晶
CN107663207B (zh) *	2016-07-27	2021-07-30	南京圣和药业股份有限公司	一种egfr激酶抑制剂的甲磺酸盐结晶及制备方法
CN107663208B (zh) *	2016-07-27	2021-10-15	南京圣和药业股份有限公司	一种新型egfr激酶抑制剂的药用盐及其制备方法与用途
EP3490974B1 (en)	2016-08-01	2023-12-06	Tenacia Biotechnology (Hong Kong) Co., Limited	Spiro-lactam nmda receptor modulators and uses thereof
AU2017306164B2 (en)	2016-08-01	2021-10-21	Tenacia Biotechnology (Hong Kong) Co., Limited	Spiro-lactam NMDA modulators and methods of using same
WO2018026792A1 (en)	2016-08-01	2018-02-08	Aptinyx Inc.	Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
IL286107B2 (en)	2016-08-01	2024-09-01	Aptinyx Inc	Spiro-lactam nmda receptor modulators and usesthereof
SG10202101055VA (en)	2016-08-01	2021-03-30	Aptinyx Inc	Spiro-lactam nmda receptor modulators and uses thereof
CA3033370A1 (en)	2016-08-15	2018-02-22	Neupharma, Inc.	Certain chemical entities, compositions, and methods
CN106366022B (zh) *	2016-08-19	2018-03-13	上海工程技术大学	一种用于制备azd9291的中间体及其制备方法和应用
CN106366072B (zh) *	2016-08-19	2018-12-07	上海工程技术大学	一种azd9291的制备方法
CN106397407B (zh) *	2016-08-31	2018-09-04	浙江科聚化工有限公司	抗肿瘤药物azd9291衍生物的制备方法
CN106432231B (zh) *	2016-09-09	2018-06-12	无锡佰翱得生物科学有限公司	Azd9291的药用盐、及其晶型和制备方法
US10654851B2 (en) *	2016-09-19	2020-05-19	Nanjing Chuangte Pharmaceutical Technology Co., Ltd.	Deuterated 3-(4,5-substituted aminopyrimidine)phenyl derivatives and use thereof
CN107955019B (zh) *	2016-10-17	2021-09-14	广东众生药业股份有限公司	一种egfr抑制剂的盐型、晶型及其制备方法
WO2018073839A1 (en)	2016-10-18	2018-04-26	Mylan Laboratories Limited	Amorphous osimertinib mesylate, processes for its preparation and solid amorphous dispersions thereof
AU2017345574A1 (en) *	2016-10-19	2019-05-23	United States Government As Represented By The Department Of Veterans Affairs	Compositions and methods for treating cancer
CN106496196B (zh) *	2016-10-20	2019-07-02	南京雷科星生物技术有限公司	一种喹唑啉、吡啶并嘧啶或则双并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途
CN106543060B (zh) *	2016-10-31	2018-11-06	湖南欧亚药业有限公司	一种奥斯替尼甲磺酸盐的制备方法
CN108299419B (zh) *	2017-01-11	2022-04-26	南京圣和药业股份有限公司	一种新型egfr激酶抑制剂的几种新晶型及其制备方法
PL3514153T3 (pl)	2017-01-26	2022-01-17	Hanmi Pharm. Co., Ltd.	Związek pirymidynowy i jego zastosowanie farmaceutyczne
WO2018156812A1 (en) *	2017-02-22	2018-08-30	G1 Therapeutics, Inc.	Treatment of egfr-driven cancer with fewer side effects
US11395821B2 (en)	2017-01-30	2022-07-26	G1 Therapeutics, Inc.	Treatment of EGFR-driven cancer with fewer side effects
TWI796326B (zh)	2017-03-24	2023-03-21	日商第一三共股份有限公司	含有ａｘｌ抑制劑與ｅｇｆｒ酪胺酸激酶抑制藥的醫藥品及其用途
CN106883216B (zh) *	2017-04-06	2020-03-13	张家港威胜生物医药有限公司	一种奥希替尼的制备方法
CN108503627A (zh) *	2017-04-19	2018-09-07	郑州泰基鸿诺医药股份有限公司	用作egfr抑制剂的2,4-二取代苯-1,5-二胺衍生物及其应用
AR111469A1 (es) *	2017-04-21	2019-07-17	Yuhan Corp	Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
CN106967050A (zh) *	2017-05-11	2017-07-21	北京工业大学	一种azd9291的制备方法
CN108929311B (zh) *	2017-05-22	2020-07-28	焦玉奇	2-(2,4,5-取代苯胺)嘧啶衍生物
WO2018214886A1 (zh)	2017-05-24	2018-11-29	浙江同源康医药股份有限公司	一种氘代azd9291的晶型、制备方法及用途
CN107176954B (zh) *	2017-06-02	2019-01-11	无锡双良生物科技有限公司	一种egfr抑制剂的药用盐及其晶型、制备方法和应用
CN108707139B (zh) *	2017-06-13	2021-04-06	北京鞍石生物科技有限责任公司	氨基嘧啶类化合物及其制备方法和应用
BR112019026483A2 (pt)	2017-06-16	2020-07-14	Beta Pharma, Inc.	formulação farmacêutica de n-(2-(2-(dimetilamina)etoxi)-4-metoxi-5-((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amina)fenil)acrilamida e seus sais
WO2019001425A1 (zh) *	2017-06-27	2019-01-03	浙江同源康医药股份有限公司	一种氘代奥斯替尼衍生物及其应用
CN107095873A (zh) *	2017-06-28	2017-08-29	卢凯华	具有低耐药性的抗肺癌靶向药物组合物
CN107216313B (zh) *	2017-06-29	2019-11-19	山东四环药业股份有限公司	一种抗肿瘤药物azd9291的制备方法
WO2019010619A1 (zh) *	2017-07-10	2019-01-17	焦玉奇	2-(2,4,5-取代苯胺)嘧啶衍生物
MY201038A (en)	2017-07-28	2024-01-31	Yuhan Corp	Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
LT3658552T (lt) *	2017-07-28	2023-11-27	Yuhan Corporation	N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il) amino)-4-metoksi-2-morfolinofenil)akrilamido gamybos būdas, vykdant reakciją tarp atitinkamo amino ir 3-halogen-propionilo chlorido
CN107266426A (zh) *	2017-08-15	2017-10-20	南通因诺威医药科技有限公司	2‑氨烃基嘧啶类化合物及其制备方法和用途
US11471457B2 (en)	2017-08-21	2022-10-18	Eli Lilly And Company	Method of treating epithelial growth factor receptor (EGFR) T790M-positive non-small cell lung cancer by administering a combination of a VEGFR-2 antibody and osimertinib
CN109485638B (zh) *	2017-09-12	2020-07-17	新发药业有限公司	一种奥希替尼中间体的制备方法
CN107915725B (zh) *	2017-10-20	2023-06-27	复旦大学	Azd9291的药用盐及其制备方法
WO2019099873A1 (en) *	2017-11-17	2019-05-23	The Board Of Trustees Of The University Of Illinois	Cancer therapy by degrading dual mek signaling
BR112020013915A2 (pt)	2018-01-08	2020-12-01	G1 Therapeutics, Inc.	regime de dosagem para liberação, e, método para tratar um câncer dependente de replicação de cdk4/6 em um humano
WO2019152696A1 (en) *	2018-01-31	2019-08-08	Aptinyx Inc.	Spiro-lactam nmda receptor modulators and uses thereof
JP7210599B2 (ja)	2018-01-31	2023-01-23	アプティニックスインコーポレイテッド	スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
CA3090528A1 (en) *	2018-02-08	2019-08-15	Neupharma, Inc.	Certain chemical entities, compositions, and methods
TWI868714B (zh)	2018-02-12	2025-01-01	瑞典商阿斯特捷利康公司	用於治療非小細胞肺癌之奧希替尼
JP2021514398A (ja) *	2018-02-20	2021-06-10	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法
JP2021514011A (ja) *	2018-02-20	2021-06-03	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法
CN108250187B (zh) *	2018-03-01	2021-01-05	中国科学院上海药物研究所	吲哚-1-碳酸酯类化合物、其制备方法和应用
CN108191861B (zh) *	2018-03-01	2020-10-02	天津大学	N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-反式-2,4-戊二烯酰胺
WO2019175093A1 (en)	2018-03-12	2019-09-19	Astrazeneca Ab	Method for treating lung cancer
CN109666024A (zh) *	2018-03-20	2019-04-23	兰州大学	2-氧嘧啶类化合物及其制备方法和用途
CN108218839A (zh) *	2018-03-20	2018-06-29	上药康丽（常州）药业有限公司	一种抗肿瘤药物azd9291的制备方法
CN108484579A (zh) *	2018-03-28	2018-09-04	黑龙江鑫创生物科技开发有限公司	一种微通道反应器合成奥希替尼中间体的方法
CN108530450B (zh) *	2018-05-03	2021-03-30	赖建智	具有egfr抑制活性的化合物、制备方法及其在疾病治疗中的应用
MX2020012063A (es)	2018-05-14	2021-04-13	Takeda Pharmaceuticals Co	Sales farmaceuticas de derivados de pirimidina y metodo de tratamiento de trastornos.
CN112119074A (zh) *	2018-05-15	2020-12-22	益方生物科技（上海）有限公司	Egfr抑制剂
CN110606842B (zh) *	2018-06-15	2021-06-01	上海艾力斯医药科技股份有限公司	吡啶胺基嘧啶衍生物的制备方法及其中间体
CN110698461B (zh) *	2018-07-09	2024-04-05	上海翰森生物医药科技有限公司	第三代egfr抑制剂的制备方法
KR101954370B1 (ko)	2018-07-25	2019-03-05	한미약품 주식회사	피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
AU2019354771A1 (en)	2018-10-05	2021-04-01	The Board Of Trustees Of The University Of Illinois	Combination therapy for the treatment of uveal melanoma
CN109134435B (zh) *	2018-10-29	2023-01-03	湖南大学	一种奥希替尼azd9291的合成方法
CN111233774B (zh) *	2018-11-28	2023-04-14	鲁南制药集团股份有限公司	一种胺基嘧啶类化合物
KR20210107069A (ko)	2018-12-21	2021-08-31	다이이찌 산쿄 가부시키가이샤	항체-약물 컨쥬게이트와 키나아제 저해제의 조합
CN113227073B (zh) *	2019-01-05	2022-09-16	山东轩竹医药科技有限公司	Egfr酪氨酸激酶的选择性抑制剂的盐及其晶型
CN111410651B (zh) *	2019-01-05	2021-06-04	山东轩竹医药科技有限公司	酪氨酸激酶抑制剂的盐及其晶型
PH12021551985A1 (en)	2019-02-22	2022-08-22	Hanmi Pharmaceutical Co Ltd	Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
CN113773304B (zh) *	2019-02-25	2023-03-10	江苏豪森药业集团有限公司	抗耐药抗肿瘤egfr抑制剂的制备方法
CN111606889B (zh) *	2019-02-25	2023-03-07	上海翰森生物医药科技有限公司	4-(1-环丙基-1h-吲哚-3-基)-n-苯基嘧啶-2-胺衍生物的制备方法
CN109928956B (zh) *	2019-02-27	2020-10-13	杭州偶联医药科技有限公司	一种靶向泛素化降解egfr蛋白的化合物及其药物组合物和应用
WO2020192302A1 (zh) *	2019-03-27	2020-10-01	广州必贝特医药技术有限公司	含嘧啶的三取代咪唑类化合物及其应用
CN111747950B (zh)	2019-03-29	2024-01-23	深圳福沃药业有限公司	用于治疗癌症的嘧啶衍生物
MX2021011810A (es)	2019-03-29	2021-10-26	Astrazeneca Ab	Osimertinib para su uso en el tratamiento de cancer de pulmon de celulas no peque?as.
WO2020206603A1 (zh) *	2019-04-09	2020-10-15	河南真实生物科技有限公司	2-(2，4，5-取代苯氨基)嘧啶衍生物及其晶形b
CN109942550A (zh) *	2019-04-15	2019-06-28	广州医科大学附属第一医院（广州呼吸中心）	11c标记的egfr正电子示踪剂及其制备方法和应用
AU2020264808B2 (en)	2019-05-01	2025-01-02	Clexio Biosciences Ltd.	Methods of treating pruritus
MA55909A (fr)	2019-05-05	2022-03-16	Qilu Regor Therapeutics Inc	Inhibiteurs de cdk
US20220340547A1 (en) *	2019-05-22	2022-10-27	Shanghi Hansoh Biosoh Biomedical Co., Ltd.	Indole derivative-containing inhibitor, preparation method therefor and application thereof
US12350265B2 (en)	2019-06-27	2025-07-08	Hanmi Pharm. Co., Ltd.	Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents
CN110283162B (zh) *	2019-07-09	2022-04-05	辽宁大学	一种表皮生长因子受体抑制剂及其应用
CN110483486B (zh) *	2019-09-17	2024-01-26	鲁南制药集团股份有限公司	一种奥西替尼酮咯酸盐晶型及其制备方法
US12012413B2 (en)	2019-11-11	2024-06-18	Tenacia Biotechnology (Hong Kong) Co., Limited	Methods of treating painful diabetic peripheral neuropathy
WO2021094379A1 (en)	2019-11-12	2021-05-20	Astrazeneca Ab	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2021111462A1 (en) *	2019-12-02	2021-06-10	Natco Pharma Limited	An improved process for the preparation of osimertinib mesylate
CA3164995A1 (en)	2019-12-20	2021-06-24	Erasca, Inc.	Tricyclic pyridones and pyrimidones
JP2023510426A (ja)	2020-01-20	2023-03-13	アストラゼネカ・アクチエボラーグ	癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
IL272441B (en) *	2020-02-03	2021-08-31	Ottek Ltd	System and method for driving an endoscope
CN113372331B (zh) *	2020-03-10	2023-09-12	鲁南制药集团股份有限公司	一种奥希替尼一水合物新晶型
CN113372332B (zh) *	2020-03-10	2023-09-12	鲁南制药集团股份有限公司	一种奥希替尼新晶型
CN111303123B (zh) *	2020-03-31	2021-08-31	南京雷正医药科技有限公司	2-(2,4,5-取代苯胺基)嘧啶化合物及其应用
CN111285852A (zh) *	2020-04-02	2020-06-16	广州博济医药生物技术股份有限公司	氘代奥希替尼药用盐的晶型及其制备方法
CN111303124A (zh) *	2020-04-08	2020-06-19	北京赛思源生物医药技术有限公司	一种甲磺酸奥希替尼的新晶体
US20210369709A1 (en) *	2020-05-27	2021-12-02	Astrazeneca Ab	EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
US10988479B1 (en)	2020-06-15	2021-04-27	G1 Therapeutics, Inc.	Morphic forms of trilaciclib and methods of manufacture thereof
CN113801101A (zh) *	2020-06-15	2021-12-17	鲁南制药集团股份有限公司	Azd9291-2-酮戊二酸盐及其制备方法
CN113929663B (zh) *	2020-06-29	2025-06-17	鲁南制药集团股份有限公司	Azd9291-2-吲哚甲酸盐及其制备方法
CN113929664A (zh) *	2020-07-13	2022-01-14	鲁南制药集团股份有限公司	Azd9291-3,5-吡啶二羧酸盐及其制备方法
CN113968845A (zh) *	2020-07-24	2022-01-25	鲁南制药集团股份有限公司	Azd9291-没食子酸盐及其制备方法
US20230321098A1 (en)	2020-08-25	2023-10-12	Loxo Oncology, Inc.	Osimertinib and selpercatinib combinations for the treatment of egfr- and ret-associated cancers
EP4217071A1 (en)	2020-09-23	2023-08-02	Erasca, Inc.	Tricyclic pyridones and pyrimidones
CN112430231B (zh) *	2020-11-06	2022-09-30	德州德药制药有限公司	一种azd9291的工业化制备方法
CN112358468B (zh) *	2020-11-10	2022-03-22	德州德药制药有限公司	一种工业化合成azd9291的方法
WO2022105882A1 (zh) *	2020-11-19	2022-05-27	上海翰森生物医药科技有限公司	一种含吲哚类衍生物的盐、晶型及其制备方法和应用
US11780824B2 (en) *	2020-12-16	2023-10-10	Scinopharm Taiwan, Ltd.	Process for preparing osimertinib or a salt thereof
WO2022133345A1 (en)	2020-12-18	2022-06-23	Erasca, Inc.	Tricyclic pyridones and pyrimidones
CN117479943A (zh)	2021-06-15	2024-01-30	基因泰克公司	组合疗法中的egfr抑制剂和perk活化剂及其用于治疗癌症的用途
CN113387935B (zh) *	2021-07-23	2022-06-10	苏州雅深智慧科技有限公司	抑制三突变表皮生长因子受体酪氨酸激酶的化合物及用途
MX2024000261A (es) *	2021-08-06	2024-03-14	Abbisko Therapeutics Co Ltd	Derivado de pirimidina o piridina, metodo de preparacion del mismo y aplicacion del mismo en la industria farmaceutica.
CA3229553A1 (en) *	2021-09-02	2023-03-09	Synthon B.V.	A process for making osimertinib
CN113683612B (zh) *	2021-09-07	2022-06-17	山东铂源药业股份有限公司	一种帕布昔利布的制备方法
JP7702205B2 (ja) *	2021-09-15	2025-07-03	株式会社東芝	新規アミン化合物、酸性ガス吸収剤、酸性ガスの除去方法及び酸性ガス除去
CN116099006A (zh) *	2021-11-10	2023-05-12	上海交通大学医学院附属新华医院	奥西替尼及其药学上可接受的盐在制备急性髓细胞白血病药物中的应用
CN114014847B (zh) *	2021-12-08	2023-11-03	滨州医学院	一种含苯并噻吩嘧啶衍生物及其制备方法和在制备抗肿瘤药物中的应用
CN114380806B (zh) *	2022-03-24	2022-06-10	中国药科大学	2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用
KR20240168418A (ko)	2022-03-31	2024-11-29	아스트라제네카 아베	암 치료를 위한 akt 억제제와 조합된 표피 성장 인자 수용체(egfr) 티로신 키나아제 억제제
AR128999A1 (es)	2022-04-07	2024-07-03	Astrazeneca Ab	Proceso mejorado para la fabricación de osimertinib
US20240116926A1 (en)	2022-04-28	2024-04-11	Astrazeneca Ab	Heteroaromatic compounds
WO2023209084A1 (en)	2022-04-28	2023-11-02	Astrazeneca Ab	Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209088A1 (en)	2022-04-28	2023-11-02	Astrazeneca Ab	Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en)	2022-04-28	2023-11-02	Astrazeneca Ab	Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023213850A1 (en) *	2022-05-03	2023-11-09	Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne)	Inhibitors of tau proteins
KR20250029133A (ko)	2022-06-27	2025-03-04	아스트라제네카 아베	암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제를 포함하는 조합물
WO2024003241A1 (en)	2022-06-30	2024-01-04	Astrazeneca Ab	Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
TW202421146A (zh)	2022-07-08	2024-06-01	瑞典商阿斯特捷利康公司	用於治療癌症的上皮生長因子受體酪胺酸激酶抑制劑與ｈｇｆ受體抑制劑的組合
CN115650974B (zh) *	2022-08-04	2024-06-18	天津大学	N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-顺式戊二烯酰胺衍生物及应用
CA3267911A1 (en) *	2022-09-19	2024-03-28	Advenchen Pharmaceuticals, LLC	NEW PYRIMIDINE COMPOUND USED AS A KINASE INHIBITOR WITH BIOLOGICAL ACTIVITY ON EGFR MUTANTS
CN116655601B (zh) *	2023-06-05	2025-08-29	河南应用技术职业学院	一种奥希替尼的合成方法
WO2025124936A1 (en)	2023-12-15	2025-06-19	Synthon B.V.	A process for making osimertinib
WO2025245045A1 (en)	2024-05-21	2025-11-27	The Regents Of The University Of California	Methods of treating lung cancer
WO2026009146A1 (en)	2024-07-01	2026-01-08	Hetero Labs Limited	Benzimidazole compounds as egfr inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9523675D0 (en)	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
AU719434B2 (en)	1996-02-13	2000-05-11	Astrazeneca Ab	Quinazoline derivatives as VEGF inhibitors
ES2169355T3 (es)	1996-03-05	2002-07-01	Astrazeneca Ab	Derivados de 4-anilinoquinazolina.
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
GB9714249D0 (en)	1997-07-08	1997-09-10	Angiogene Pharm Ltd	Vascular damaging agents
GB9900334D0 (en)	1999-01-07	1999-02-24	Angiogene Pharm Ltd	Tricylic vascular damaging agents
GB9900752D0 (en)	1999-01-15	1999-03-03	Angiogene Pharm Ltd	Benzimidazole vascular damaging agents
MXPA01008182A (es)	1999-02-10	2003-08-20	Astrazeneca Ab	Derivados de quinazolina como inhibidores de angiotensina.
EP1289952A1 (en)	2000-05-31	2003-03-12	AstraZeneca AB	Indole derivatives with vascular damaging activity
UA73993C2 (uk)	2000-06-06	2005-10-17	Астразенека Аб	Хіназолінові похідні для лікування пухлин та фармацевтична композиція
MXPA02012903A (es)	2000-07-07	2004-07-30	Angiogene Pharm Ltd	Derivados de colquinol como inhibidores de angiogenesis.
CA2411160A1 (en)	2000-07-07	2002-01-17	Angiogene Pharmaceuticals Limited	Colchinol derivatives as vascular damaging agents
US6881737B2 (en) *	2001-04-11	2005-04-19	Amgen Inc.	Substituted triazinyl acrylamide derivatives and methods of use
DE10237722A1 (de) *	2002-08-17	2004-08-19	Aventis Pharma Deutschland Gmbh	Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
WO2006068826A2 (en) *	2004-12-21	2006-06-29	Smithkline Beecham Corporation	2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
GB0500492D0 (en)	2005-01-11	2005-02-16	Cyclacel Ltd	Compound
KR101313702B1 (ko)	2005-02-03	2013-10-04	와이어쓰	제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
AR056763A1 (es)	2005-11-03	2007-10-24	Vertex Pharma	Aminopirimidinas sustituidas con tiazol o pirazol,utiles como agentes anticancer y composiciones farmaceuticas que las contienen.
GB0524436D0 (en)	2005-11-30	2006-01-11	Novartis Ag	Organic compounds
US7807673B2 (en) *	2005-12-05	2010-10-05	Glaxosmithkline Llc	2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
JP2009541318A (ja)	2006-06-22	2009-11-26	メルクエンドカムパニーインコーポレーテッド	チロシンキナーゼ阻害剤
WO2008009458A1 (en) *	2006-07-21	2008-01-24	Novartis Ag	2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
TWI475996B (zh)	2007-10-19	2015-03-11	Celgene Avilomics Res Inc	雜芳基化合物及其用途
US7989465B2 (en) *	2007-10-19	2011-08-02	Avila Therapeutics, Inc.	4,6-disubstituted pyrimidines useful as kinase inhibitors
DK2361248T3 (en)	2008-06-27	2019-01-14	Celgene Car Llc	Heteroberl compounds and uses thereof
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
MY156789A (en)	2008-09-05	2016-03-31	Celgene Avilomics Res Inc	Algorithm for designing irreversible inhibitors
WO2010042337A1 (en)	2008-10-07	2010-04-15	Merck Sharp & Dohme Corp.	Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (zh) *	2008-10-27	2014-01-15	上海睿星基因技术有限公司	激酶抑制剂及其在药学中的用途
EP2440559B1 (en) *	2009-05-05	2018-01-10	Dana-Farber Cancer Institute, Inc.	Egfr inhibitors and methods of treating disorders
KR101256018B1 (ko) *	2009-08-20	2013-04-18	한국과학기술연구원	단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
RU2012114902A (ru)	2009-09-16	2013-10-27	Авила Терапьютикс, Инк.	Конъюгаты и ингибиторы протеинкиназы
WO2011053476A1 (en) *	2009-11-02	2011-05-05	Abbott Laboratories	Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition
WO2011079231A1 (en)	2009-12-23	2011-06-30	Gatekeeper Pharmaceutical, Inc.	Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
US20130137709A1 (en)	2010-05-05	2013-05-30	Nathanael S. Gray	Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
BR122014012788B1 (pt)	2010-06-23	2022-04-19	Hanmi Science Co., Ltd	Derivados de pirimidina fundidos, seus usos, e composição farmacêutica para inibição da atividade de tirosina quinase
TW201219383A (en)	2010-08-02	2012-05-16	Astrazeneca Ab	Chemical compounds
CA2832504C (en) *	2011-05-04	2019-10-01	Ariad Pharmaceuticals, Inc.	Compounds for inhibiting cell proliferation in egfr-driven cancers
JP5427321B2 (ja)	2011-07-27	2014-02-26	アストラゼネカアクチボラグ	２−（２，４，５−置換−アニリノ）ピリミジン化合物

2012
- 2012-07-25 JP JP2013541431A patent/JP5427321B2/ja active Active
- 2012-07-25 HR HRP20160135TT patent/HRP20160135T1/hr unknown
- 2012-07-25 DK DK15192658.1T patent/DK3009431T3/en active
- 2012-07-25 CN CN201410287447.1A patent/CN104109151B/zh active Active
- 2012-07-25 KR KR1020147011325A patent/KR101691268B1/ko active Active
- 2012-07-25 SI SI201230455T patent/SI2736895T1/sl unknown
- 2012-07-25 CN CN201510639051.3A patent/CN105254616B/zh active Active
- 2012-07-25 PL PL17194307T patent/PL3333161T3/pl unknown
- 2012-07-25 DK DK20157798.8T patent/DK3686193T3/da active
- 2012-07-25 PT PT201577988T patent/PT3686193T/pt unknown
- 2012-07-25 EP EP22189028.8A patent/EP4119551A1/en active Pending
- 2012-07-25 EA EA201792394A patent/EA033733B1/ru unknown
- 2012-07-25 ES ES12759801.9T patent/ES2564671T3/es active Active
- 2012-07-25 EP EP22158770.2A patent/EP4086246A1/en not_active Withdrawn
- 2012-07-25 ES ES20157927T patent/ES2900230T3/es active Active
- 2012-07-25 ME MEP-2020-87A patent/ME03785B/me unknown
- 2012-07-25 DK DK17194307.9T patent/DK3333161T3/da active
- 2012-07-25 SM SM20200208T patent/SMT202000208T1/it unknown
- 2012-07-25 SG SG10201910984XA patent/SG10201910984XA/en unknown
- 2012-07-25 SI SI201231771T patent/SI3333161T1/sl unknown
- 2012-07-25 CA CA2881987A patent/CA2881987C/en active Active
- 2012-07-25 ES ES20157798T patent/ES2914854T3/es active Active
- 2012-07-25 BR BR122014026150-0A patent/BR122014026150B1/pt active IP Right Grant
- 2012-07-25 CN CN201510507888.2A patent/CN105175396B/zh active Active
- 2012-07-25 ES ES17194307T patent/ES2791308T3/es active Active
- 2012-07-25 CN CN201410287156.2A patent/CN104109161B/zh active Active
- 2012-07-25 PE PE2013002532A patent/PE20141700A1/es active IP Right Grant
- 2012-07-25 SG SG10201402860QA patent/SG10201402860QA/en unknown
- 2012-07-25 PH PH1/2013/502312A patent/PH12013502312A1/en unknown
- 2012-07-25 CA CA2881991A patent/CA2881991C/en active Active
- 2012-07-25 US US13/557,871 patent/US8946235B2/en active Active
- 2012-07-25 PL PL15192658T patent/PL3009431T3/pl unknown
- 2012-07-25 BR BR122014026114-4A patent/BR122014026114B1/pt active IP Right Grant
- 2012-07-25 HU HUE12759801A patent/HUE026429T2/en unknown
- 2012-07-25 PT PT171943079T patent/PT3333161T/pt unknown
- 2012-07-25 MX MX2014000528A patent/MX2014000528A/es unknown
- 2012-07-25 KR KR1020137003097A patent/KR101410902B1/ko active Active
- 2012-07-25 RS RS20211378A patent/RS62542B1/sr unknown
- 2012-07-25 SM SM20210652T patent/SMT202100652T1/it unknown
- 2012-07-25 PT PT201579273T patent/PT3686194T/pt unknown
- 2012-07-25 CA CA2882018A patent/CA2882018C/en active Active
- 2012-07-25 ME MEP-2017-290A patent/ME02887B/me unknown
- 2012-07-25 EP EP15192658.1A patent/EP3009431B1/en active Active
- 2012-07-25 HU HUE15192658A patent/HUE037645T2/hu unknown
- 2012-07-25 HU HUE17194307A patent/HUE049060T2/hu unknown
- 2012-07-25 ME MEP-2016-34A patent/ME02382B/me unknown
- 2012-07-25 EP EP20157927.3A patent/EP3686194B1/en active Active
- 2012-07-25 AU AU2012288626A patent/AU2012288626C1/en active Active
- 2012-07-25 EP EP17194307.9A patent/EP3333161B1/en active Active
- 2012-07-25 EP EP12759801.9A patent/EP2736895B1/en active Active
- 2012-07-25 MY MYPI2013702541A patent/MY161925A/en unknown
- 2012-07-25 MX MX2015017622A patent/MX377900B/es unknown
- 2012-07-25 MY MYPI2019007672A patent/MY194532A/en unknown
- 2012-07-25 PT PT151926581T patent/PT3009431T/pt unknown
- 2012-07-25 RS RS20200459A patent/RS60190B1/sr unknown
- 2012-07-25 CN CN201280033773.9A patent/CN103702990B/zh active Active
- 2012-07-25 CN CN201510641921.0A patent/CN105198862B/zh active Active
- 2012-07-25 BR BR122014026094-6A patent/BR122014026094B1/pt active IP Right Grant
- 2012-07-25 HR HRP20211682TT patent/HRP20211682T1/hr unknown
- 2012-07-25 SG SG2013081716A patent/SG194783A1/en unknown
- 2012-07-25 EA EA201391491A patent/EA024421B1/ru active Protection Beyond IP Right Term
- 2012-07-25 PL PL12759801T patent/PL2736895T3/pl unknown
- 2012-07-25 DK DK20157927.3T patent/DK3686194T3/da active
- 2012-07-25 SI SI201231963T patent/SI3686194T1/sl unknown
- 2012-07-25 BR BR112014001768-9A patent/BR112014001768B1/pt active IP Right Grant
- 2012-07-25 KR KR1020147008572A patent/KR101422619B1/ko active Active
- 2012-07-25 SI SI201231167T patent/SI3009431T1/en unknown
- 2012-07-25 WO PCT/GB2012/051783 patent/WO2013014448A1/en not_active Ceased
- 2012-07-25 LT LTEP20157927.3T patent/LT3686194T/lt unknown
- 2012-07-25 RS RS20160094A patent/RS54653B1/sr unknown
- 2012-07-25 LT LTEP15192658.1T patent/LT3009431T/lt unknown
- 2012-07-25 DK DK12759801.9T patent/DK2736895T3/da active
- 2012-07-25 PL PL20157798T patent/PL3686193T3/pl unknown
- 2012-07-25 RS RS20171309A patent/RS56679B1/sr unknown
- 2012-07-25 CN CN201510639096.0A patent/CN105348266B/zh active Active
- 2012-07-25 EP EP20157798.8A patent/EP3686193B1/en active Active
- 2012-07-25 SG SG10201402857QA patent/SG10201402857QA/en unknown
- 2012-07-25 PL PL20157927T patent/PL3686194T3/pl unknown
- 2012-07-25 SG SG10201910986QA patent/SG10201910986QA/en unknown
- 2012-07-25 CA CA2843109A patent/CA2843109C/en active Active
- 2012-07-25 CA CA2881993A patent/CA2881993C/en active Active
- 2012-07-25 LT LTEP17194307.9T patent/LT3333161T/lt unknown
- 2012-07-25 EA EA201690328A patent/EA029488B1/ru not_active IP Right Cessation
- 2012-07-25 HU HUE20157927A patent/HUE056365T2/hu unknown
- 2012-07-25 ES ES15192658.1T patent/ES2654177T3/es active Active
- 2012-07-26 TW TW103124452A patent/TWI555743B/zh active
- 2012-07-26 AR ARP120102716 patent/AR087336A1/es active IP Right Grant
- 2012-07-26 UY UY34219A patent/UY34219A/es not_active Application Discontinuation
- 2012-07-26 TW TW105130486A patent/TWI583386B/zh active
- 2012-07-26 TW TW101127018A patent/TWI465445B/zh active
2013
- 2013-06-05 JP JP2013118744A patent/JP5537704B2/ja active Active
- 2013-10-31 IL IL229199A patent/IL229199A/en active IP Right Grant
- 2013-11-13 DO DO2013000263A patent/DOP2013000263A/es unknown
- 2013-11-14 CL CL2013003281A patent/CL2013003281A1/es unknown
- 2013-11-19 EC ECSP13013033 patent/ECSP13013033A/es unknown
- 2013-11-20 GT GT201300288A patent/GT201300288A/es unknown
- 2013-11-28 CO CO13279940A patent/CO6811863A2/es active IP Right Grant
- 2013-11-29 CR CR20130629A patent/CR20130629A/es unknown
- 2013-12-06 NI NI201300134A patent/NI201300134A/es unknown
2014
- 2014-01-10 MX MX2020013020A patent/MX2020013020A/es unknown
- 2014-03-31 JP JP2014071530A patent/JP5977779B2/ja active Active
- 2014-12-19 US US14/576,721 patent/US9732058B2/en active Active
2015
- 2015-06-15 PH PH12015501326A patent/PH12015501326A1/en unknown
- 2015-10-26 IL IL242279A patent/IL242279A/en active IP Right Grant
- 2015-10-26 IL IL242284A patent/IL242284A/en active IP Right Grant
- 2015-10-26 IL IL242286A patent/IL242286A/en active IP Right Grant
- 2015-10-26 IL IL242285A patent/IL242285A/en active IP Right Grant
- 2015-10-26 IL IL242278A patent/IL242278A/en active IP Right Grant
2016
- 2016-03-01 CY CY20161100168T patent/CY1117431T1/el unknown
- 2016-03-10 SM SM201600070T patent/SMT201600070B/xx unknown
2017
- 2017-07-13 US US15/649,068 patent/US10017493B2/en active Active
- 2017-12-18 HR HRP20171957TT patent/HRP20171957T1/hr unknown
2018
- 2018-01-03 CY CY20181100002T patent/CY1120072T1/el unknown
- 2018-05-29 US US15/991,578 patent/US20190092746A1/en not_active Abandoned
2019
- 2019-06-19 US US16/445,709 patent/US10858336B2/en active Active
2020
- 2020-04-20 HR HRP20200624TT patent/HRP20200624T1/hr unknown
- 2020-05-12 CY CY20201100434T patent/CY1123210T1/el unknown
- 2020-11-12 US US17/096,167 patent/US11524951B2/en active Active
2021
- 2021-11-17 CY CY20211100994T patent/CY1125405T1/el unknown
2024
- 2024-01-08 US US18/406,693 patent/US20240182441A1/en not_active Abandoned
- 2024-08-28 US US18/818,196 patent/US20240425476A1/en active Pending

Also Published As

Publication number	Publication date
BR122014026150A2 (pt)	2019-05-28
PH12013502312A1 (en)	2016-07-13
CA2843109A1 (en)	2013-01-31
TW201319057A (zh)	2013-05-16
ECSP13013033A (es)	2014-01-31
IL242284A0 (en)	2015-11-30
BR122014026094A2 (pt)	2019-08-20
EP3686194A1 (en)	2020-07-29
ME03785B (me)	2021-04-20
HUE049060T2 (hu)	2020-08-28
HK1192549A1 (zh)	2014-08-22
IL242279A (en)	2016-07-31
RS60190B1 (sr)	2020-06-30
SG194783A1 (en)	2013-12-30
IL242286A (en)	2016-07-31
PH12015501326B1 (en)	2015-09-14
NZ617393A (en)	2014-11-28
CR20130629A (es)	2014-03-12
SG10201910984XA (en)	2020-01-30
HK1221216A1 (en)	2017-05-26
PT3686194T (pt)	2021-11-11
IL242284A (en)	2016-07-31
CN105198862B (zh)	2018-01-23
ES2914854T3 (es)	2022-06-17
AR087336A1 (es)	2014-03-19
IL229199A0 (en)	2014-01-30
SG10201910986QA (en)	2020-01-30
ES2791308T3 (es)	2020-11-03
IL242285A (en)	2016-07-31
JP2014139226A (ja)	2014-07-31
LT3686194T (lt)	2021-11-25
EP2736895A1 (en)	2014-06-04
KR101691268B1 (ko)	2016-12-29
CN105175396B (zh)	2018-01-16
US10858336B2 (en)	2020-12-08
ME02382B (me)	2016-06-20
CY1125405T1 (el)	2023-03-24
DK3333161T3 (da)	2020-05-18
IL229199A (en)	2015-11-30
IL242278A0 (en)	2015-11-30
DOP2013000263A (es)	2014-01-31
CN104109151A (zh)	2014-10-22
AU2012288626A8 (en)	2013-09-26
TWI583386B (zh)	2017-05-21
ES2564671T3 (es)	2016-03-28
US20130053409A1 (en)	2013-02-28
EA201792394A2 (ru)	2018-03-30
KR20140030089A (ko)	2014-03-11
KR101422619B1 (ko)	2014-07-24
EP3333161A1 (en)	2018-06-13
MX2014000528A (es)	2014-05-01
AU2012288626B2 (en)	2015-05-07
MY161925A (en)	2017-05-15
IL242286A0 (en)	2015-11-30
EP4086246A1 (en)	2022-11-09
CN105254616A (zh)	2016-01-20
CA2881987C (en)	2017-04-25
PT3009431T (pt)	2017-12-26
SI3686194T1 (sl)	2022-01-31
ES2900230T3 (es)	2022-03-16
EA201391491A1 (ru)	2014-08-29
CA2881991A1 (en)	2013-01-31
IL242285A0 (en)	2015-11-30
EP3333161B1 (en)	2020-02-19
EP4119551A1 (en)	2023-01-18
JP2013544273A (ja)	2013-12-12
LT3009431T (lt)	2018-01-10
US20190092746A1 (en)	2019-03-28
TW201443040A (zh)	2014-11-16
ES2654177T3 (es)	2018-02-12
RS54653B1 (sr)	2016-08-31
PT3686193T (pt)	2022-05-20
CN103702990B (zh)	2015-09-09
SI3009431T1 (en)	2018-01-31
US20240425476A1 (en)	2024-12-26
EP3686193B1 (en)	2022-03-02
PL3686193T3 (pl)	2022-06-13
DK3009431T3 (en)	2018-01-08
US20210130318A1 (en)	2021-05-06
EA029488B1 (ru)	2018-04-30
HK1192554A1 (en)	2014-08-22
CN104109161B (zh)	2016-08-17
WO2013014448A1 (en)	2013-01-31
SG10201402860QA (en)	2014-08-28
CA2881991C (en)	2016-10-25
BR122014026094B1 (pt)	2020-10-13
EP3686194B1 (en)	2021-09-15
US20240182441A1 (en)	2024-06-06
CN103702990A (zh)	2014-04-02
EP3009431B1 (en)	2017-10-25
US9732058B2 (en)	2017-08-15
HUE056365T2 (hu)	2022-02-28
DK3686193T3 (da)	2022-05-30
PL2736895T3 (pl)	2016-05-31
RS56679B1 (sr)	2018-03-30
JP5537704B2 (ja)	2014-07-02
TWI555743B (zh)	2016-11-01
SG10201402857QA (en)	2014-08-28
UY34219A (es)	2013-02-28
PL3333161T3 (pl)	2020-08-24
HRP20171957T1 (hr)	2018-02-09
US8946235B2 (en)	2015-02-03
EP2736895B1 (en)	2016-01-06
BR112014001768A2 (pt)	2017-02-14
HK1256370A1 (en)	2019-09-20
CN105254616B (zh)	2017-10-17
CY1120072T1 (el)	2018-12-12
US20190389834A1 (en)	2019-12-26
HUE026429T2 (en)	2016-05-30
PE20141700A1 (es)	2014-11-20
CN105348266A (zh)	2016-02-24
CN105348266B (zh)	2018-04-10
HRP20160135T1 (hr)	2016-03-11
US10017493B2 (en)	2018-07-10
JP5977779B2 (ja)	2016-08-24
EA033733B1 (ru)	2019-11-20
PL3686194T3 (pl)	2022-01-17
IL242279A0 (en)	2015-11-30
JP5427321B2 (ja)	2014-02-26
CO6811863A2 (es)	2013-12-16
KR101410902B1 (ko)	2014-06-20
BR122014026150B1 (pt)	2020-10-13
AU2012288626A1 (en)	2013-05-02
IL242278A (en)	2016-12-29
CY1117431T1 (el)	2017-04-26
HUE037645T2 (hu)	2018-09-28
EA201792394A3 (ru)	2018-07-31
CN105175396A (zh)	2015-12-23
CA2881993A1 (en)	2013-01-31
CA2882018C (en)	2017-04-25
BR122014026114B1 (pt)	2021-01-12
DK3686194T3 (da)	2021-11-22
EA201690328A1 (ru)	2016-11-30
MX377900B (es)	2025-03-10
BR122014026114A2 (pt)	2019-08-20
CA2882018A1 (en)	2013-01-31
LT3333161T (lt)	2020-05-11
ME02887B (me)	2018-04-20
US20150119379A1 (en)	2015-04-30
EP3009431A1 (en)	2016-04-20
HRP20211682T1 (hr)	2022-03-04
EP3686193A1 (en)	2020-07-29
HRP20200624T1 (hr)	2020-07-10
MY194532A (en)	2022-11-30
GT201300288A (es)	2017-10-09
SI3333161T1 (sl)	2020-07-31
KR20140047741A (ko)	2014-04-22
CN104109161A (zh)	2014-10-22
JP2014094930A (ja)	2014-05-22
US20180162832A1 (en)	2018-06-14
EA024421B1 (ru)	2016-09-30
US11524951B2 (en)	2022-12-13
CN105198862A (zh)	2015-12-30
CA2843109C (en)	2015-06-16
CN104109151B (zh)	2017-04-12
CY1123210T1 (el)	2021-10-29
PT3333161T (pt)	2020-05-18
SMT202100652T1 (it)	2022-01-10
TW201700099A (zh)	2017-01-01
PH12015501326A1 (en)	2015-09-14
AU2012288626C1 (en)	2015-09-17
CA2881993C (en)	2017-05-09
NI201300134A (es)	2014-02-12
SMT202000208T1 (it)	2020-05-08
BR112014001768B1 (pt)	2019-02-05
MX2020013020A (es)	2022-06-14
SI2736895T1 (sl)	2016-03-31
DK2736895T3 (da)	2016-02-29
RS62542B1 (sr)	2021-12-31
TWI465445B (zh)	2014-12-21
CL2013003281A1 (es)	2014-07-25
KR20140062181A (ko)	2014-05-22
PL3009431T3 (pl)	2018-02-28
CA2881987A1 (en)	2013-01-31

Publication	Publication Date	Title
SMT201600070B (it)	2016-04-29	Derivati di 2-(2,4,5-anilino-sostituita) pirimidina come modulatori di egfr utili per trattare il cancro
SMT201600274B (it)	2016-08-31	Processo per la preparazione di composti utili come inibitori del sglt2
SMT201700052B (it)	2017-03-08	2-(azaindol-2-il)benzimidazoli come inibitori di pad4
SMT201600198B (it)	2016-08-31	Derivati di 1,2,4-triazina-4-ammina
DK2922828T3 (da)	2020-08-31	4,6-diamino-pyrimidin-derivater som bmi-1-inhibitorer til at behandle cancer
EP2706853A4 (en)	2014-11-05	AMINOPYRIMIDINE AS SYK-HEMMER
SMT201500270B (it)	2016-01-08	Derivati di pirrolotriazinone come inibitori di pi3k
SMT201600169B (it)	2016-07-01	Nuovi composti per la modulazione di fxr (nr1 h4)
BR112014028424A2 (pt)	2018-04-24	compostos de pirimidina para o tratamento de câncer
SMT201600020B (it)	2016-02-25	Derivati di benzilammina come inibitori di callicreina plasmatica
EP2900665A4 (en)	2016-03-23	TRIAZOLYL DERIVATIVES AS SYK-HEMMER
DK3330257T3 (da)	2020-04-27	Pyrimidinderivater til behandling af virusinfektioner
LT3026064T (lt)	2019-01-25	Antikūnai, skirti vėžio gydymui, ekspresuojantys klaudiną 6
EP2667714A4 (en)	2014-07-30	METHOD OF PREPARING 4-AMINO-5-FLUORO-3-HALO-6- (SUBSTITUTE) PICOLINATES
BR112013024378A2 (pt)	2016-12-13	novos derivados de pirimidina
EP2685992A4 (en)	2014-09-10	AMINOCHINOLINE AS A KINASEHEMMER
ME03392B (me)	2020-01-20	Prolek derivati (e)-n-meтil-n-( (з-метi lbenzofuran-2-il)meтil)-3-(7 -okso-5 ,6, 7,8-тетrанidr0-1,8-nafтiridin-3-il)akrilamida
LT3566712T (lt)	2021-03-10	Kompozicija, skirta kontroliuojamai kiaušidžių stimuliacijai
EP2934525A4 (en)	2016-06-08	THIAZOLSUBSTITUTED AMINOPYRIDINE AS MILTSTYROSINKINASE INHIBITOR
IT1399223B1 (it)	2013-04-11	Apparato per lavorare cornici di infissi.
BR112013018942A2 (pt)	2018-05-22	processo para o preparo de 4-amino-3-cloro-5-fluro-6(substituído) picolinatos.
EP2699566A4 (en)	2014-09-03	PHENYL-ISOXAZOLE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF